| Description | Navivumab (CT-P23) is a monoclonal antibody targeting the hemagglutinin HA of the influenza A virus, effectively neutralizing strains H1, H2, H5, and H9 by binding to the HA2 stem fusion domain [1]. |
| molecular weight | N/A |
| CAS | 1443004-16-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |